Recon: Alzheimer’s drugmakers undeterred on accelerated approval despite Aduhelm coverage decision; Japan cancels a third of its AstraZeneca vaccine order

• FDA's Califf on accelerated approval: 'In God, we trust, everyone else must bring good evidence' (Fierce)
• ‘Precedents are important’: Aduhelm coverage restrictions could shape the future of accelerated approval (STAT)
• Alzheimer's drugmakers seek accelerated FDA review despite U.S. coverage decision (Reuters)
• Pfizer taps David Denton from Lowe's as CFO (Reuters)
• Walgreens trial over its part in Florida opioid crisis set to begin (Reuters)
• Biotechs take a beating in first round of #AACR22 as weak data cripple share prices (Endpoints)

• Moderna recalls thousands of COVID vaccine doses in Europe (Reuters)
• Drugmakers pledge speedier European market launches to avert stricter regulation (Reuters)
• India's COVID-19 vaccine prices cut as booster program is extended (Reuters)
• Taiwan orders Pfizer's COVID-19 pill as infections rise (Reuters)
• Japan cancels a third of contracted AstraZeneca vaccine purchase (Reuters)
• ICH Statement on the situation in Ukraine (ICH)

• WHO says it is analysing two new Omicron COVID sub-variants (Reuters)
• Demand for Covid vaccines falls amid waning appetite for booster shots (FT)
• Germany agrees deal with CureVac, GSK for mRNA vaccines until 2029 (Reuters)
• Vaccine group Gavi secures $4.8 billion in funding pledges for COVAX (Reuters)
• Incomplete data likely masks a rise in U.S. Covid cases as focus on infection counts fades (NBC)
• There’s an uptick in U.S. vaccinations, and older Americans are the reason (NBC)

• AACR: Bristol Myers details Opdivo's presurgery lung cancer win, with an early sign of survival benefit (Fierce)
• AACR22: Amgen reveals new long-term data for Lumakras, looking to keep pressing market advantage over Mirati (Endpoints)
• AACR22: Affimed's NK cell therapy produces more patient responses — and more durability questions (Endpoints)
• An mRNA vaccine boost may help CAR T-therapy treat solid cancers (STAT)
• Flagship-backed microbiome company Kaleido Biosciences shuts down (Endpoints)
• Scoop: AbbVie drops IBS drug Viberzi in Canada, 'devastating' patients (Endpoints)
• Exclusive: Flagship snags another CEO-partner, on a personal mission, to lead its tRNA boat (Endpoints)

• Fitbit tails Apple Watch with FDA-cleared algorithm to passively check for afib (Fierce) (TechCrunch)
• FDA official: Draft cybersecurity guidance has 'teeth' (MedtechDive)
• Pfizer to drop $74M for COVID cough-screening smartphone app developer (Fierce)

• Seagen scores $41.8M in Enhertu patent case against Daiichi Sankyo (Fierce) (Law360)
• Vanda Sues US FDA For Documents Backing Complete Response For Hetlioz Jet Lag Indication (Pink Sheet)
• When Congress Seeks Cos.' Nonpublic Info From Regulators (Law360)